1,227 件 ・ 関連度順
概要と使いどころ
Performs root cause analysis on DAG execution failures. Traces failure propagation, identifies systemic issues, and generates actionable remediation guidance. Activate on 'failure analysis', 'root cause', 'why did it fail', 'debug failure', 'error investigation'. NOT for execution tracing (use dag-execution-tracer) or performance issues (use dag-performance-profiler).
日本語の概要は準備中です。原文の説明を表示しています。
Operations, debugging, and optimization for DAG workflows. Performs root cause analysis on failures, profiles execution performance, aggregates results from parallel branches, bridges context between nodes, and learns patterns from execution history. Activate on "DAG failed", "why did it fail", "root cause", "performance profile", "aggregate results", "merge branches", "execution patterns", "optimize DAG". NOT for planning DAGs (use dag-planner), executing DAGs (use dag-runtime), or validating outputs (use dag-quality).
日本語の概要は準備中です。原文の説明を表示しています。
Cryptographic security for agentic systems — zero-trust agent networking, signed message envelopes (JWS/JWE), capability-based security (ocaps), Merkle tree audit trails, WASM sandboxing, and formal verification. Covers CLI dev tool security, mTLS between agents, permission boundaries (least privilege for AI agents), and supply chain security for skills/plugins. Activate on: "agent security", "zero trust agents", "secure agent communication", "capability-based security", "ocap", "signed messages between agents", "agent audit trail", "sandbox agent execution", "agent permissions", "mTLS agents", "cryptographic verification", "agent supply chain", "OWASP agentic", "prove agent did X", "tamper-proof agent logs". NOT for: application-level SAST scanning (use security-auditor), network firewall rules (use infrastructure), SOC2/HIPAA compliance (organizational), or prompt injection defense (use prompt-engineer).
日本語の概要は準備中です。原文の説明を表示しています。
Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Colic et al. 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving greater sensitivity to small-effect hits than MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).
日本語の概要は準備中です。原文の説明を表示しています。
Performs gene-level association from GWAS summary statistics via genetically predicted tissue expression using FUSION, PrediXcan, S-PrediXcan, S-MultiXcan, UTMOST, MOSTWAS, kTWAS, EpiXcan, TIGAR-V2, and probabilistic fine-mapping with FOCUS and MA-FOCUS. Use when running TWAS from GWAS sumstats, prioritising candidate causal genes from a GWAS lead locus, picking single-tissue vs cross-tissue models, identifying LD-induced TWAS false positives, choosing ancestry-matched prediction weights, fine-mapping co-regulated TWAS hits, or triangulating TWAS with cis-eQTL Mendelian randomization and colocalization to nominate a causal gene.
日本語の概要は準備中です。原文の説明を表示しています。
Resolves GWAS associations to candidate causal variants and credible sets via SuSiE, susie_rss, FINEMAP, CAVIAR, DAP-G, PAINTOR, PolyFun, SuSiEx, MultiSuSiE, and FOCUS. Use when narrowing a GWAS lead SNP to a 95 percent credible set, choosing between in-sample and reference LD, calibrating non-sparse loci with SuSiE-inf or FINEMAP-inf, integrating functional priors via PolyFun, fine-mapping across ancestries with SuSiEx, diagnosing LD mismatch via estimate_s_rss and kriging_rss, handling HLA or long-range LD, or feeding credible sets into coloc.susie for colocalization.
日本語の概要は準備中です。原文の説明を表示しています。
Annotates ChIP-seq peaks to genomic features, nearest genes, ENCODE candidate cis-regulatory elements (cCREs), and regulatory domains. Uses ChIPseeker (R), HOMER annotatePeaks.pl (CLI), pyranges (Python), GREAT/rGREAT (regulatory domain gene-set enrichment), ChIP-Enrich (locus-length-adjusted), ENCODE SCREEN cCRE classification (PLS/pELS/dELS/CA-CTCF/CA-H3K4me3), and ENCODE-rE2G for cell-type-specific enhancer-gene linking. Handles nearest-TSS vs host-gene ambiguity, promoter window definition, and feature priority. Use when assigning genomic context to peaks, linking enhancer peaks to target genes, classifying peaks against ENCODE cCRE registry, or running gene-set enrichment on peak-associated genes.
日本語の概要は準備中です。原文の説明を表示しています。
This skill determines whether inpatient diabetic patients meet high-risk criteria for CGM initiation using Table 3 factors such as age ≥65 years, BMI ≤27 kg/m², type 1 diabetes, insulin regimen, and specific clinical conditions. It is triggered by clinician questions like "Should I assess this inpatient for CGM initiation based on hypoglycemia risk?" or "Is this patient a candidate for inpatient CGM?"
日本語の概要は準備中です。原文の説明を表示しています。
Decide whether commonly-excluded patients (eating disorders, elderly ≥75, upper GI disease) can actually receive a GLP-1 receptor agonist. Use when a clinician asks "can I give semaglutide to a patient with binge eating disorder / anorexia / bulimia", "is liraglutide safe in an 80-year-old", "GLP-1 with GERD or chronic gastritis", "GLP-1 in sarcopenic elderly", or anytime a patient is being ruled out for GLP-1 therapy based on a perceived contraindication. Grounded in Gorgojo-Martínez 2023 §6 (Myths or Reality).
日本語の概要は準備中です。原文の説明を表示しています。
Performs a structured pre‑prescription evaluation of mental/psychological status, prior diabetes self‑care adherence, willingness/interest in CSII, and availability for follow‑up visits. Triggers include: 'Evaluating pump candidacy', 'Pre‑pump checklist: psych, adherence, motivation, follow-up'.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests that clinicians continue CSII in hospitalized patients with type 1 or type 2 diabetes when the institution has clear protocols for evaluating pump candidates and appropriate monitoring and safety procedures. Trigger phrases include: 'Admitted patient on pump, check hospital pump policy' and 'Inpatient with diabetes using pump, verify institutional guidelines'.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends transsphenoidal selective adenomectomy (TSS) by an experienced pituitary surgeon as the optimal treatment for Cushing's disease in pediatric and adult patients. Use when a patient with ACTH-dependent Cushing syndrome is a surgical candidate; triggers include overt Cushing's syndrome, elevated UFC or late-night salivary cortisol, and pituitary MRI showing an adenoma.
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests administering a glucocorticoid antagonist (e.g., mifepristone) in patients with Cushing's disease who have diabetes or glucose intolerance and are not surgical candidates or have persistent disease after transsphenoidal surgery. Consider when encountering persistent hypercortisolism after TSS, contraindications to surgery, or comorbid diabetes/glucose intolerance requiring medical control.
日本語の概要は準備中です。原文の説明を表示しています。
Determines when adrenal venous sampling (AVS) is indicated for functional subtyping of primary aldosteronism (PA) when surgical treatment is feasible and desired by the patient. Triggered when a clinician confirms PA diagnosis and asks 'Do I need AVS for subtyping?' or evaluates surgical candidacy.
日本語の概要は準備中です。原文の説明を表示しています。
Determines whether to perform adrenal venous sampling (AVS) to lateralize aldosterone excess in patients with confirmed primary aldosteronism (PA) who are being evaluated for surgical treatment. Indicated when surgery is feasible and desired by the patient, or when subtype workup is planned for a surgical candidate, especially in those younger than 35 years with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions on CT.
日本語の概要は準備中です。原文の説明を表示しています。
Determines whether adrenal venous sampling (AVS) is needed in addition to CT for lateralizing primary aldosteronism before surgery. Trigger phrases include "patient with primary aldosteronism considering surgery", "unilateral adrenal adenoma on CT", "surgical candidate", and "age <35 with hypokalemia and >1‑cm adenoma".
日本語の概要は準備中です。原文の説明を表示しています。
Cycle-end retrospective converting recurring judgment failures into durable enforcement. Reviews the cycle's friction — repeated user corrections, guard trips, RCA themes, integrate failures — and turns each recurring one into a landmines.md entry, then proposes graduation candidates up the enforcement funnel (landmine → advisory hook → hard gate). Pairs with standup: standup says what shipped and what's next; retrospective says what kept going wrong and how to stop it structurally. Writes only memory entries and a report — graduation proposals are advisory and require the normal seed.md amendment path to become enforcement. Invoke at the end of a release cycle, an epic, or any stretch of work with repeated friction.
日本語の概要は準備中です。原文の説明を表示しています。
Azure Identity SDK for Rust authentication. Use for DeveloperToolsCredential, ManagedIdentityCredential, ClientSecretCredential, and token-based authentication.
日本語の概要は準備中です。原文の説明を表示しています。
Automate recruiting and hiring workflows in Ashby -- manage candidates, jobs, applications, interviews, and notes through natural language commands.
日本語の概要は準備中です。原文の説明を表示しています。
Advogado criminalista especializado em Maria da Penha, violencia domestica, feminicidio, direito penal brasileiro, medidas protetivas, inquerito policial e acao penal.
日本語の概要は準備中です。原文の説明を表示しています。
End-of-week reflection report. Mines your Claude Code transcripts from the last 7 days to produce a self-contained HTML file with (1) the topics/areas you explored, (2) distilled key learnings with live-searched further-reading links, and (3) a token/command/skill/ctx-stack usage summary. Use when the user says "week in review", "weekly review", "what did I learn this week", "my week", or runs /week-in-review.
日本語の概要は準備中です。原文の説明を表示しています。
Find the first batch of foreign-trade prospect companies from public web, LinkedIn, and user-authorized data sources such as customs exports, trade show lists, association directories, CRM/Excel files, or historical customer data, then output a conservative, structured candidate list ready for lead screening.
日本語の概要は準備中です。原文の説明を表示しています。
Discover prospect companies from a structured OpenClaw search brief, including public search and user-authorized data sources, then output a conservative candidate list ready for lead screening.
日本語の概要は準備中です。原文の説明を表示しています。